This Article Full Text Full Text (PDF) All Versions of this Article: 115/20/2637    most recent CIRCULATIONAHA.106.661397v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Freudenberger, R. S. Search for Related Content PubMed PubMed Citation Articles by Freudenberger, R. S. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB AMIODARONE HYDROCHLORIDE Medline Plus Health Information Heart Failure Stroke Related Collections Congestive Thrombosis risk factors Related Article

(Circulation. 2007;115:2637-2641.)
© 2007 American Heart Association, Inc.

Heart Failure

Risk of Thromboembolism in Heart Failure

An Analysis From the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)

Ronald S. Freudenberger, MD; Anne S. Hellkamp, MS; Jonathan L. Halperin, MD; Jeanne Poole, MD; Jill Anderson, BSN; George Johnson, BSEE; Daniel B. Mark, MD, MPH; Kerry L. Lee, PhD; Gust H. Bardy, MD, for the SCD-HeFT Investigators

From the Robert Wood Johnson Medical School (R.S.F.), New Brunswick, NJ; Duke Clinical Research Institute (A.S.H., D.B.M., K.L.L.), Durham, NC; Mount Sinai School of Medicine (J.L.H.), New York, NY; University of Washington (J.P.), Seattle, Wash; and Seattle Institute for Cardiac Research (J.A., G.J., G.H.B.), Seattle, Wash.

Correspondence to Ronald Freudenberger, MD, Department of Medicine, Robert Wood Johnson Medical School, Suite 6100, 125 Paterson St, New Brunswick, NJ 08903. E-mail r.freudenberger{at}yahoo.com

Received August 28, 2006; accepted March 20, 2007.

Background— In patients with heart failure, rates of clinically apparent stroke range from 1.3% to 3.5% per year. Little is known about the incidence and risk factors in the absence of atrial fibrillation. In the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT), 2521 patients with moderate heart failure were randomized to receive amiodarone, implanted cardioverter-defibrillators (ICDs), or placebo.

Methods and Results— We determined the incidence of stroke or peripheral or pulmonary embolism in patients with no history of atrial fibrillation (n=2114), predictors of thromboembolism and the relationship to left ventricular ejection fraction. Median follow-up was 45.5 months. Kaplan-Meier estimates (95% CIs) for the incidence of thromboembolism by 4 years were 4.0% (3.0% to 4.9%), with 2.6% (1.1% to 4.1%) in patients randomized to amiodarone, 3.2% (1.8% to 4.7%) in patients randomized to ICD, and 6.0% (4.0% to 8.0%) in patients randomized to placebo (approximate rates of 0.7%, 0.8%, and 1.5% per year, respectively). By multivariable analysis, hypertension (P=0.021) and decreasing left ventricular ejection fraction (P=0.023) were significant predictors of thromboembolism; treatment with amiodarone or ICD treatment was a significant predictor of thromboembolism-free survival (P=0.014 for treatment effect; hazard ratio [95% CI] versus placebo, 0.57 [0.33 to 0.99] for ICD; 0.44 [0.24 to 0.80] for amiodarone). Inclusion of atrial fibrillation during follow-up in the multivariable model did not affect the significance of treatment assignment as a predictor of thromboembolism.

Conclusions— In the SCD-HeFT patient cohort, which reflects contemporary treatment of patients with moderately symptomatic systolic heart failure, patients experienced thromboembolism events at a rate of 1.7% per year without antiarrhythmic therapy. Those treated with amiodarone or ICDs had lower risk of thromboembolism than those given placebo. Hypertension at baseline and lower ejection fraction were independent predictors of risk.

---

 

CLINICAL PERSPECTIVE

Related Article:

Issue Highlights
Circulation 2007 115: 2591. [Extract] [Full Text]

This article has been cited by other articles:

				T. L. Ripley and E. Nutescu Anticoagulation in patients with heart failure and normal sinus rhythm Am. J. Health Syst. Pharm., January 15, 2009; 66(2): 134 - 141. [Abstract] [Full Text] [PDF]

				E. Doufekias, A. Z. Segal, and J. R. Kizer Cardiogenic and aortogenic brain embolism. J. Am. Coll. Cardiol., March 18, 2008; 51(11): 1049 - 1059. [Abstract] [Full Text] [PDF]

				N U Weir An update on cardioembolic stroke Postgrad. Med. J., March 1, 2008; 84(989): 133 - 142. [Abstract] [Full Text] [PDF]

				R. A. de Boer and D. J. van Veldhuisen Letter by de Boer and van Veldhuisen Regarding Article, "Risk of Thromboembolism in Heart Failure: An Analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)" Circulation, January 1, 2008; 117(1): e7 - e7. [Full Text] [PDF]

				R. S. Freudenberger, A. S. Hellkamp, D. B. Mark, K. L. Lee, J. L. Halperin, J. Poole, J. Anderson, G. Johnson, G. H. Bardy, and for the SCD-HeFT Investigators Response to Letter Regarding Article, "Risk of Thromboembolism in Heart Failure: An Analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT)" Circulation, January 1, 2008; 117(1): e8 - e8. [Full Text] [PDF]